GENE EDITING 101
All Companies
🇨🇭

Cimeio Therapeutics

Private

Shielded cell therapy via gene editing

Cimeio Therapeutics is a Swiss biotech developing 'shielded' cell therapies using gene editing. Their approach edits both donor stem cells and therapeutic antibodies so that transplanted cells are selectively protected from targeted therapy — enabling safer stem cell transplants without full immune ablation.

Founded2020
HQBasel, Switzerland
CEOLukas Josefsson
StatusPrivate
Total Funding$150M

Pipeline

Drug / ProgramIndicationPhaseTechnology
CIM-001Hematologic malignanciesPhase 1Shielded stem cells

Key People

Lukas JosefssonCEO

Related Articles

CRISPR Companies to Watch in 2026: Who's Leading the Gene Editing Revolution?
Biotech Companies
Market Analysis

CRISPR Companies to Watch in 2026: Who's Leading the Gene Editing Revolution?

A comprehensive look at the CRISPR companies shaping the future of medicine in 2026, from approved therapies to next-generation editing platforms.

Mar 16, 20266 min read